We have Lexaria Bioscience Chairman and CEO Chris Bunka stopping by for a fascinating discussion on disruption, the art of being a CEO, and their innovative technology DehydraTECH™. DehydraTECH™ improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs. Chris is a published author and was previously a serial entrepreneur for over three decades.

In today's episode, you'll hear:

Chris's origin story and what makes him tick

The art of being a CEO

The thought process behind pivoting Lexaria (and how you can think about pivoting)

How Lexaria became what it is today

Why you must have your ethics and values in order

What is DehydraTECH™

The many potential benefits of DehydraTECH™

The process to get listed on NASDAQ and some things to expect

How Chris goes about adding team members (and the number one thing he looks for)

What's on the horizon for Lexaria

Some of the significant health issues Lexaria is attacking

Chris's wellness habits

And much more

Connect with Chris:

Website: https://www.lexariabioscience.com/ 

Investment platforms: Type LEXX

Connect with Julian:

Superhuman Optimization & Enhancement Program: https://theartoffitnessandlife.com/us/

Connect with me on Twitter: https://twitter.com/thejulianhayes

Connect with me on LinkedIn: https://www.linkedin.com/in/julianhayes